Compare McKesson Corporation (MCK) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Charles Schwab Corporation Common Stock — how do they compare? McKesson Corporation trades at $824.45 (market cap $97.35B), while Charles Schwab Corporation Common Stock trades at $100.46 (market cap $178.33B). The key difference: Charles Schwab Corporation Common Stock is the larger of the two by market cap, and Charles Schwab Corporation Common Stock pays the higher dividend (1.25%). Which is the better fit depends on your goals.
| MCK | SCHW | |
|---|---|---|
Market Cap | $97.35B | $178.33B |
Sector | Health | Financials |
52-Week High | $995.69 | $107.21 |
52-Week Low | $659.01 | $85.35 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Charles Schwab (SCHW) trades at $102.01, up 0.44% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $1.43 and revenue growth accelerating to $23.92 billion in 2025. Analyst sentiment remains positive with 58% buy ratings and a $120 consensus price target representing 18% upside potential. Recent news highlights strong trading activity and earnings optimism ahead of Q2 results.
The outlook remains favorable with earnings momentum and operational strength driving potential upside. Key opportunities include continued trading revenue growth and margin expansion, while risks involve interest rate sensitivity and market volatility. The stock's current valuation at 20.19 P/E appears reasonable given the company's profitability and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
